ClinicalTrials.gg
RecruitingNCT07721571Updated Oct 6, 2026

Nephrostomy Tract Infiltration for Pain Control After PCNL

An interventional study of Bupivacaine and Intravenous Tramadol and Paracetamol in Postoperative Pain and Kidney Calculi, sponsored by Hitit University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Hitit University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Oct 6, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 364 studies testing bupivacaine in Pain, Postoperative — 57 open to participants now, 60 under way, 5 of them phase 3. Bupivacaine · Pain, Postoperative.

Planned enrollment
205th of 364
60 · median 70
Started
2026
with 21 others
No phase
111 of 364
26 open now
Primary completion
2027-01
later than 36 of 59 live
Registered
351st of 364
by date

Among the 364 studies testing bupivacaine in Pain, Postoperative, this one is the 205th largest by planned enrollment, is one of 22 that started in 2026, is one of 111 with no phase, reaches primary completion later than 36 of the 59 other live ones, and was the 351st registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

57 of the 364 studies testing bupivacaine in Pain, Postoperative are open now, in 8 countries. Recruiting first, the newest first:

51 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About bupivacaine

Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 364 studies testing bupivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

This prospective, randomized, controlled clinical trial aims to evaluate the effectiveness of nephrostomy tract local anesthetic infiltration for postoperative pain control in patients undergoing prone percutaneous nephrolithotomy. Eligible patients will be randomly assigned to either a control group receiving standard systemic postoperative analgesia or an intervention group receiving standard analgesia plus infiltration of 20 mL of 0.25% bupivacaine along the nephrostomy tract at the end of surgery. Postoperative pain will be assessed using the Visual Analog Scale at 1, 6, 12, and 24 hours. Secondary outcomes will include time to first analgesic requirement, total opioid consumption during the first 24 hours, need for rescue analgesia, time to mobilization, length of hospital stay, and treatment-related complications. The study is designed to determine whether nephrostomy tract infiltration provides a simple, safe, and effective adjunct for reducing pain and analgesic consumption after percutaneous nephrolithotomy.

03

Conditions studied

  • Postoperative Pain
  • Kidney Calculi

Keywords

  • local anesthetic infiltration
  • Percutaneous nephrolithotomy
  • peritubal infiltration
  • postoperative pain
04

Who can participate

The criteria were revised on the registry on Oct 6, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 to 75 years
  • Scheduled to undergo elective percutaneous nephrolithotomy in the prone position
  • Classified as (ASA) physical status I-III
  • Able to understand and complete postoperative pain assessments using the Visual Analog Scale (VAS)
  • Willing to participate in the study
  • Provision of written

Exclusion criteria

Exclusion Criteria:

  • Known allergy or to bupivacaine or other local anesthetic agents
  • Coagulopathy or bleeding disorder
  • Chronic opioid use
  • History of a neurological disorder that may affect pain perception or assessment
  • Neurological or psychiatric condition preventing reliable postoperative pain assessment
  • Active urinary tract infection or sepsis
  • (ASA) physical status IV or higher
  • Requirement for multiple percutaneous access tracts
  • Bilateral percutaneous nephrolithotomy
  • Requirement for postoperative intensive care
  • Refusal or inability to provide written
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Nephrostomy Tract Bupivacaine Infiltration

    Participants in this arm will receive standard postoperative systemic analgesia. In addition, at the end of percutaneous nephrolithotomy, 20 mL of 0.25% bupivacaine will be infiltrated along the nephrostomy tract, including the skin, subcutaneous tissue, muscular layers, and tissues surrounding the nephrostomy tract.

    Drug: Bupivacaine · Drug: Intravenous Tramadol and Paracetamol

  • Active comparator
    Standard Systemic Analgesia

    Participants in this arm will receive the standard postoperative systemic analgesia protocol, including intravenous tramadol and intravenous paracetamol. Rescue opioid analgesia will be administered when clinically required. No local or regional analgesic intervention will be performed.

    Drug: Intravenous Tramadol and Paracetamol

Interventions

  • A total of 20 mL of 0.25% bupivacaine will be administered by local infiltration along the nephrostomy tract at the end of surgery. The infiltration will include the skin, subcutaneous tissue, muscular layers, and tissues surrounding the nephrostomy tract.

    Also known as: Bupivacaine hydrochloride, Nephrostomy tract local anesthetic infiltration, Peritubal bupivacaine infiltration

  • DrugIntravenous Tramadol and Paracetamol

    Drug pages: TramadolStudies of TramadolTramadol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · AcetaminophenStudies of AcetaminophenAcetaminophen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Standard postoperative systemic analgesia consisting of intravenous tramadol and intravenous paracetamol will be administered according to the institutional analgesia protocol. Rescue opioid analgesia will be provided when clinically required.

    Also known as: Standard postoperative analgesia, Intravenous tramadol and acetaminophen

06

What researchers measure

Primary outcomes

  1. Postoperative Pain Intensity Assessed Using the Visual Analog Scale

    Postoperative pain intensity will be assessed using the Visual Analog Scale (VAS). Patients will rate their pain on a scale from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. VAS scores will be compared between the nephrostomy tract bupivacaine infiltration group and the standard systemic analgesia group.

    Time frame: At 1, 6, 12, and 24 hours after surgery

Secondary outcomes

  1. Time to First Rescue Analgesic Requirement

    The time from the end of surgery to the first administration of rescue analgesic medication will be recorded in minutes. A longer duration indicates a prolonged postoperative analgesic effect.

    Time frame: From the end of surgery until the first rescue analgesic administration, within the first 24 postoperative hours

  2. Total Opioid Consumption During the First 24 Postoperative Hours

    The total amount of opioid analgesics administered during the first 24 hours after surgery will be recorded. When different opioid agents are used, doses will be converted to intravenous morphine milligram equivalents for comparison between groups.

    Time frame: During the first 24 hours after surgery

  3. Requirement for Rescue Analgesia

    The number and proportion of participants requiring at least one dose of rescue analgesic medication will be compared between the study groups.

    Time frame: During the first 24 hours after surgery

07

Study locations

1 of 1 sites recruiting
  • Department of Urology, Hitit University Çorum Erol Olçok Training and Research Hospital, Çorum, Türkiye
    Çorum, Çorum 19040, Turkey (Türkiye)
    Recruiting
    • MUSA EKİCİ · Contactmusaekici@hitit.edu.tr · +90 505 751 6341
    • AHMET TAŞCI · Sub investigator
    • METİN KIZGIN · Sub investigator
08

References and documents

Publications

  • Shah HN, Shah RH, Sodha HS, Khandkar AA, Gokhale A. A randomized control trial evaluating efficacy of nephrostomy tract infiltration with bupivacaine after tubeless percutaneous nephrolithotomy. J Endourol. 2012 May;26(5):478-83. doi: 10.1089/end.2011.0465. Epub 2011 Dec 22. PubMed 22191494 ↗
  • Arshad Z, Zaidi SZ, Jamshaid A, Qureshi AH. Post operative pain control in percutaneous nephrolithotomy. J Pak Med Assoc. 2018 May;68(5):702-704. PubMed 29885165 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jan 2027, 5 months after the start.

Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 5 months is below that.

Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2026
First posted
Jul 23, 2026
StartActual
Jul 17, 2026
Primary completionEst.
Jan 11, 2027
CompletionEst.
Jun 11, 2027
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
2 inclusion criteria edited; 11 exclusion criteria added, 1 removed
What changed in the criteria
Inclusion criteria
  • EditedClassified as American Society of Anesthesiologists (ASA) physical status I-III
  • EditedAble to understand and complete postoperative pain assessments using the Visual Analog Scale (VAS)
Exclusion criteria
  • RemovedKnown allergy or hypersensitivity to bupivacaine or other local anesthetic agents Coagulopathy or clinically significant bleeding disorder Chronic opioid use History of a neurological disorder that may affect pain perception or assessment Neurological or psychiatric condition preventing reliable postoperative pain assessment Active urinary tract infection or sepsis American Society of Anesthesiologists physical status IV or higher Requirement for multiple percutaneous access tracts Bilateral percutaneous nephrolithotomy Requirement for postoperative intensive care Refusal or inability to provide written informed consent
  • AddedKnown allergy or hypersensitivity to bupivacaine or other local anesthetic agents
  • AddedCoagulopathy or clinically significant bleeding disorder
  • AddedChronic opioid use
  • AddedHistory of a neurological disorder that may affect pain perception or assessment
  • AddedNeurological or psychiatric condition preventing reliable postoperative pain assessment
  • AddedActive urinary tract infection or sepsis
  • AddedAmerican Society of Anesthesiologists (ASA) physical status IV or higher
  • AddedRequirement for multiple percutaneous access tracts
  • AddedBilateral percutaneous nephrolithotomy
  • AddedRequirement for postoperative intensive care
  • AddedRefusal or inability to provide written informed consent
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Eligibility 2 inclusion criteria edited; 11 exclusion criteria added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • EditedClassified as American Society of Anesthesiologists (ASA) physical status I-III
    • EditedAble to understand and complete postoperative pain assessments using the Visual Analog Scale (VAS)
    Exclusion criteria
    • RemovedKnown allergy or hypersensitivity to bupivacaine or other local anesthetic agents Coagulopathy or clinically significant bleeding disorder Chronic opioid use History of a neurological disorder that may affect pain perception or assessment Neurological or psychiatric condition preventing reliable postoperative pain assessment Active urinary tract infection or sepsis American Society of Anesthesiologists physical status IV or higher Requirement for multiple percutaneous access tracts Bilateral percutaneous nephrolithotomy Requirement for postoperative intensive care Refusal or inability to provide written informed consent
    • AddedKnown allergy or hypersensitivity to bupivacaine or other local anesthetic agents
    • AddedCoagulopathy or clinically significant bleeding disorder
    • AddedChronic opioid use
    • AddedHistory of a neurological disorder that may affect pain perception or assessment
    • AddedNeurological or psychiatric condition preventing reliable postoperative pain assessment
    • AddedActive urinary tract infection or sepsis
    • AddedAmerican Society of Anesthesiologists (ASA) physical status IV or higher
    • AddedRequirement for multiple percutaneous access tracts
    • AddedBilateral percutaneous nephrolithotomy
    • AddedRequirement for postoperative intensive care
    • AddedRefusal or inability to provide written informed consent

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07721571
Lead sponsor
Hitit University
Responsible party
Mustafa Serdar CAGLAYAN (Assistant Professor, MD, Hitit University) — Principal investigator
First posted
Jul 23, 2026
Start date
Jul 17, 2026
Primary completion
Jan 11, 2027 (estimated)
Completion
Jun 11, 2027 (estimated)
Last update
Oct 6, 2026

Study contacts

MUSTAFA SERDAR ÇAĞLAYAN
Contact
serdar.09.09@hotmail.com
+905074311951

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupivacaine

Start the discussion